Gardedam Therapeutics, Inc. acquired Cantabio Pharmaceuticals Inc. (OTCPK:CTBO) in a reverse merger transaction on December 17, 2015. As a result of the Merger, the Gardedam shareholders will receive 15.5 million shares of Cantabio common stock representing 56.8% of the issued and outstanding shares of Cantabio common stock. The respective Boards of Directors of Cantabio and Gardedam deem it advisable that the transaction is in the best interests of their respective stockholders. A precondition to the transaction, was that Dr. Gergley Toth return 13.5 million shares of Cantabio common stock to treasury, Simon Peace return 1 million shares of Cantabio common stock to treasury and Dr. Thomas Roger Sawyer return 1 million shares of Cantabio common stock to treasury. The precondition was satisfied on the date of the transaction. The transaction is subject to regulatory approval, third party approval and shareholders' approval of Gardedam Therapeutics.

Gardedam Therapeutics, Inc. completed the acquisition of Cantabio Pharmaceuticals Inc. (OTCPK:CTBO) in a reverse merger transaction on December 17, 2015.